YY1-mediated DUXAP8 facilitates HCC progression via modulating DEPDC1 expression

Area of Science:

• Molecular Biology
• Oncology
• RNA Biology

Background:

• Long noncoding RNA DUXAP8 is linked to various cancers, including hepatocellular carcinoma (HCC).
• The precise mechanisms of DUXAP8 in HCC development and treatment remain unclear.
• DUXAP8 expression correlates with disease progression, necessitating further study.

Purpose of the Study:

• To investigate the role and mechanisms of DUXAP8 in hepatocellular carcinoma.
• To determine the impact of DUXAP8 on HCC cell proliferation and metastasis.
• To elucidate the regulatory network involving DUXAP8, YY1, and DEPDC1.

Main Methods:

• DUXAP8 expression analysis in HCC cell lines and patient tissues.
• In vitro assays to assess proliferation and metastasis.
• RNA immunoprecipitation and luciferase reporter assays to study regulatory relationships.

Main Results:

• DUXAP8 is upregulated in HCC and enhances proliferation and metastasis.
• DUXAP8, YY1, and DEPDC1 expression correlates with clinical parameters.
• YY1 regulates DUXAP8, which modulates DEPDC1 via miR-7-5p sponging and HNRNPF-mediated mRNA stabilization.

Conclusions:

• DUXAP8 is a key driver of HCC proliferation and metastasis through specific molecular pathways.
• The DUXAP8/miR-7-5p and DUXAP8/HNRNPF pathways regulate DEPDC1 expression in HCC.
• DUXAP8 presents a potential therapeutic target and biomarker for liver cancer management.